(Q36518462)

English

Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers

scientific article published on January 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

14 August 2017

1 reference

Europe PubMed Central

Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers (English)

1 reference

Europe PubMed Central

14 August 2017

chelation therapy

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

George J Kontoghiorghes

1

object named as

George J Kontoghiorghes

1 reference

Europe PubMed Central

14 August 2017

publication date

1 January 2006

1 reference

Europe PubMed Central

14 August 2017

1 reference

Europe PubMed Central

14 August 2017

30

1 reference

Europe PubMed Central

14 August 2017

2

1 reference

Europe PubMed Central

14 August 2017

329-347

1 reference

Europe PubMed Central

14 August 2017

A genetic view of iron homeostasis

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642674

21 January 2018

Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642674

21 January 2018

Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642674

21 January 2018

The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642674

21 January 2018

Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642674

21 January 2018

Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642674

21 January 2018

Acute bone marrow aplasia associated with intravenous administration of deferoxamine (desferrioxamine)

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642674

21 January 2018

Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642674

21 January 2018

New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators. A review

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642674

21 January 2018

Long-term trial with the oral iron chelator 1, 2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642674

21 January 2018

Site specificity of iron removal from transferrin by alpha-ketohydroxypyridine chelators.

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642674

21 January 2018

The study of iron mobilisation from transferrin using alpha-ketohydroxy heteroaromatic chelators

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642674

21 January 2018

Fast biological iron chelators: kinetics of iron removal from human diferric transferrin by multidentate hydroxypyridonates

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642674

21 January 2018

Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients.

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642674

21 January 2018

Prophylactic use of deferiprone (L1) and magnetic resonance imaging T2* or T2 for preventing heart disease in thalassaemia

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642674

21 January 2018

Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642674

21 January 2018

Do we need more iron-chelating drugs?

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642674

21 January 2018

Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642674

21 January 2018

Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642674

21 January 2018

Radiographic and MRI features of deferiprone-related arthropathy of the knees in patients with beta-thalassemia

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642674

21 January 2018

Chelation therapy in beta-thalassemia: an optimistic update

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642674

21 January 2018

Ocular toxicity of high-dose intravenous desferrioxamine

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642674

21 January 2018

Ocular toxicity of desferrioxamine: light microscopic histochemical and ultrastructural findings

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642674

21 January 2018

Ocular toxicity of desferrioxamine

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642674

21 January 2018

Acute deafness and desferrioxamine

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642674

21 January 2018

Iron-chelating therapy with the new oral agent ICL670 (Exjade).

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642674

21 January 2018

Development of tridentate iron chelators: from desferrithiocin to ICL670.

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642674

21 January 2018

Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642674

21 January 2018

ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642674

21 January 2018

Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642674

21 January 2018

Effects of ICL670 (deferasirox) on cardiac iron concentrations

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642674

21 January 2018

First human studies with a high-molecular-weight iron chelator

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642674

21 January 2018

Retraction: The triterpenoid CDDO-Imidazolide induces apoptosis and enhances fludarabine-induced apoptosis of CLL B-cells

1 reference

3 January 2024

https://opencitations.net/index/api/v1/citations/10.1182/BLOOD-2003-11-3774

Identifiers

10.1080/03630260600642674

1 reference

Europe PubMed Central

14 August 2017

1 reference

Europe PubMed Central

14 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36518462&oldid=2149820832"